Furthermore, inhibitors of the CU—CPT series targeting TLR8 impede signaling pathways by stabilizing TLR8 dimers, which verifies their therapeutic potential for autoimmune diseases in transgenic mice. Here, TLR8 is linked to autoimmune disease.